Edgewise Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EWTX | SLDB | CYTK | IONS | PTCT | DSGN | |
|---|---|---|---|---|---|---|
| Market cap | 4.18B | 719.48M | 8.73B | 7.26B | 5.25B | 682.77M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -21.2 | -3.9 | -14.1 | -39.3 | 26.5 | -6.7 |
| Price/book | 9.2 | 1.9 | -50.2 | 16.4 | -31.7 | 3.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +161.56% | +7.70% | +2.88% | −38.81% | −4.80% | +64.80% |
| Today | −1.56% | −2.33% | −0.19% | −3.56% | −2.75% | −6.35% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EWTX news ›Transcript : Edgewise Therapeutics, Inc. - Special Call
Presentation Operator MessageOperator Hello, and welcome to the Edgewise Therapeutics Update Call. [Operator Instructions] As a reminder, this conference is being recorded today. If you have any... Transcript : Edgewise Therapeutics, Inc.…
Edgewise Therapeutics, Inc. : Insider Transactions
Follow insider transactions on Edgewise Therapeutics, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Edgewise Therapeutics, Inc. Biotechnology & Medical Research…
All Transcripts on Edgewise Therapeutics, Inc. (EWTX)
Find all the latest transcripts on Edgewise Therapeutics, Inc. Transcripts Edgewise Therapeutics, Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
Edgewise Therapeutics, Inc.: Official Announcements - Stock Market News
Find the latest press releases and official documents published by Edgewise Therapeutics, Inc. on MarketScreener. Press Releases Edgewise Therapeutics, Inc. Biotechnology & Medical Research All financial news and data tailored to specific…
Edgewise Therapeutics, Inc.: News in other languages | EWTX | US28036F1057
Edgewise Therapeutics, Inc.: News, information and stories for Edgewise Therapeutics, Inc. | Nasdaq: EWTX | Nasdaq Other languages Edgewise Therapeutics, Inc. Biotechnology & Medical Research All financial news and data tailored to…
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
Edgewise Therapeutics could benefit from EDG-7500's differentiated drug profile, a potentially lighter phase 3 monitoring approach and possible validation from rival studies, though elevated... Biotechnology & Medical Research Edgewise…
Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains Outperform Rating
Edgewise Therapeutics has an average rating of buy and mean price target of $50.46, according to analysts polled by FactSet. ... Biotechnology & Medical Research Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains…
Edgewise Therapeutics Doses First Patient in Trial of Investigational Heart Failure Drug
marketscreener.com Biotechnology & Medical Research Edgewise Therapeutics Doses First Patient in Trial of Investigational Heart Failure Drug Published on 10/08/2026 at 08:57 am EDT
All Transcripts on Egetis Therapeutics AB (EGTX)
Find all the latest transcripts on Egetis Therapeutics AB Transcripts Egetis Therapeutics AB Biotechnology & Medical Research All financial news and data tailored to specific country editions
Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says
Edgewise Therapeutics' EDG-7500 mechanism reveal accounts for strong clinical showing, lending confidence ahead of phase 3 trial design, RBC said in a Tuesday note. Earlier, the company unveiled... Biotechnology & Medical Research…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com10
-
prnewswire.com1
-
stockstotrade.com1
-
themarketsdaily.com1
-
timothysykes.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.